The relationship between COVID-19 vaccination and mental health outcomes has emerged as an important area of clinical investigation. While the primary focus of vaccine research has centered on physical health protection, increasing attention is being directed toward potential psychological effects. This article examines evidence regarding the development of anxiety symptoms following administration of the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine, based on a case series published in Frontiers in Psychiatry. The analysis explores potential mechanisms, clinical presentations, and therapeutic approaches while maintaining a cautious perspective given the preliminary nature of the findings.
Clinical Presentations: Anxiety Symptoms Post-Vaccination
A case series published in Frontiers in Psychiatry (2025) documented three patients who reported significant anxiety symptoms following complete vaccination with the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine between May and July 2021. The clinical manifestations observed in these cases provide insight into potential psychological sequelae of vaccination in vulnerable populations.
In the first case, a patient experienced anxiety that was managed pharmacologically with trazodone and tianeptine, resulting in clinical improvement. Subsequent examinations including computed tomography, electroencephalography, and transcranial and intracranial vessel duplex revealed age-specific and non-significant changes, suggesting no clear structural neurological basis for the anxiety symptoms.
The second case presented with a more complex clinical picture. Following administration of both the initial Pfizer vaccine on May 4, 2021, and a booster on May 25, 2021, the patient reported a significant decline in health characterized by anxiety and depression. Within 24 hours after receiving the booster, the patient experienced another episode of anxiety and depression accompanied by persistent worrying, difficulty relaxing, restlessness, weakness, an inability to leave home due to anxiety, and loss of appetite resulting in a 10 kg weight loss.
Diagnostic assessment for this second case utilized standardized measures including the ICD-10 criteria for depressive episode without somatic symptoms, as well as the Patient Health Questionnaire 9-Item Scale (PHQ-9) for depression and the Generalized Anxiety Disorder 7-item scale (GAD-7) for anxiety disorders. The patient demonstrated initial improvement with short-term antidepressant use but required hospitalization in September 2022, approximately 16 months post-vaccination, due to increased anxiety. A 30-day hospitalization with daily administration of 20 mg escitalopram led to improvement, though the patient was subsequently re-hospitalized in 2023 due to tremors and extreme anxiety.
The third case, while not detailed in the provided source material, is noted to share commonalities with the other two cases, including pre-existing psychiatric symptoms, relatively severe anxiety manifestations, and a prolonged recovery process.
Common Factors in Post-Vaccination Anxiety
Analysis of the case series identified several common factors among the three patients who developed anxiety symptoms following Pfizer-BioNTech vaccination:
- All patients had received a complete course of the Pfizer-BioNTech (BNT162b2) vaccine
- Each patient had pre-existing psychiatric symptoms prior to vaccination
- All developed relatively severe symptoms of anxiety
- Each experienced a prolonged recovery process
The authors note that these commonalities suggest potential vulnerability factors that may predispose certain individuals to psychological sequelae following vaccination. However, they emphasize that no strong similarities were identified between the three cases beyond these factors, and the underlying cause of anxiety in these cases may not be directly connected to the vaccination.
Potential Mechanisms Linking Vaccination to Anxiety
The case report authors propose several potential mechanisms that may play a role in the development of anxiety following COVID-19 vaccination:
Inflammatory processes: Systemic inflammation triggered by the immune response to the vaccine may affect neurological function and contribute to anxiety symptoms.
Changes in psychotropic metabolism: Alterations in the metabolism of psychiatric medications or endogenous neurotransmitters may occur in response to vaccination, potentially destabilizing mental health in susceptible individuals.
Autoimmune responses: The immune activation associated with vaccination may trigger autoimmune processes that affect the central nervous system.
Stress related to the vaccination itself: Anticipatory anxiety, fear of adverse effects, or psychological stress associated with the vaccination experience may contribute to symptom development.
Notably, the case series references research indicating that a depressive episode occurring prior to receiving the Pfizer-BioNTech COVID-19 vaccine may serve as a negative predictor of antibody titers, suggesting a complex interrelationship between pre-existing mental health conditions and immune response to vaccination.
Clinical Considerations and Management
The management of anxiety symptoms potentially related to COVID-19 vaccination requires careful clinical assessment and individualized treatment approaches. Based on the cases presented, several therapeutic considerations emerge:
Pharmacological Interventions
The case series documents treatment with various antidepressant medications: - Trazodone and tianeptine resulted in improvement for one patient - Short-term antidepressant use provided some benefit for another patient - Escitalopram 20 mg daily led to improvement following hospitalization for severe anxiety
These pharmacological approaches align with standard treatment protocols for anxiety and depressive disorders, though the case series does not provide sufficient data to establish specific recommendations for post-vaccination anxiety.
Diagnostic Assessment
Comprehensive diagnostic evaluation is essential for patients presenting with anxiety following vaccination. The case series utilized standardized assessment tools including: - ICD-10 diagnostic criteria - PHQ-9 for depression - GAD-7 for anxiety disorders
These tools help establish baseline symptom severity and monitor treatment response. Additional investigations, including neuroimaging and electrophysiological studies as performed in one case, may be indicated to rule out other potential causes of symptoms.
Monitoring and Follow-Up
Given the prolonged recovery process observed in the cases, extended follow-up may be necessary for patients experiencing persistent anxiety after vaccination. Regular assessment of symptom progression, treatment response, and functional impairment can guide ongoing clinical management.
Limitations and Cautions in Interpretation
The authors of the case series emphasize several important limitations and cautions regarding the interpretation of their findings:
Causality not established: The underlying cause of anxiety in these cases may not be connected to the Pfizer-BioNTech vaccination, as no definitive causal relationship can be established through case reports.
Confounding factors: Comorbidities and life events (such as head trauma, substance use including alcohol and benzodiazepines) may have contributed to the development or exacerbation of anxiety symptoms.
Reporting bias: The patients independently and actively reported their anxiety without prompting from doctors, which may have introduced reporting bias.
Generalizability concerns: The small number of cases and specific characteristics of the patients limit the generalizability of the findings.
The authors recommend that reports linking vaccination to the development of anxiety should be assessed with caution, emphasizing the need for larger, controlled studies to investigate potential relationships between COVID-19 vaccination and mental health outcomes.
Research Implications and Future Directions
The case series highlights several important areas for future investigation:
Pathogenetic mechanisms: Further research is needed to elucidate the potential biological mechanisms that could link COVID-19 vaccination to anxiety symptoms.
Vulnerable populations: Identification of pre-existing factors that may predispose individuals to psychological sequelae following vaccination could inform targeted monitoring and prevention strategies.
Longitudinal studies: Prospective longitudinal studies with larger sample sizes and control groups are needed to establish whether there is a true association between vaccination and anxiety symptoms.
Comparative research: Investigation of whether the observed psychological effects are specific to the Pfizer-BioNTech vaccine or may occur with other COVID-19 vaccines would provide valuable comparative data.
Immune-mental health interactions: Research examining the complex interrelationship between immune responses, mental health status, and vaccination outcomes could advance understanding of biopsychosocial mechanisms.
Conclusion
The case series reported in Frontiers in Psychiatry describes three patients who developed anxiety symptoms following complete vaccination with the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine. While the findings suggest a potential association between vaccination and anxiety in individuals with pre-existing psychiatric conditions, the authors emphasize the preliminary nature of these observations and the need for cautious interpretation.
The clinical presentations documented in the cases highlight the importance of comprehensive assessment and individualized treatment approaches for patients experiencing psychological symptoms following vaccination. Multiple potential mechanisms have been proposed to explain these observations, including inflammatory processes, changes in psychotropic metabolism, autoimmune responses, and vaccination-related stress.
Given the limitations of case report data and the complexity of factors that may contribute to anxiety symptoms, larger controlled studies are needed to establish whether a true causal relationship exists between COVID-19 vaccination and mental health outcomes. Until such evidence is available, clinicians should maintain a balanced perspective that acknowledges both the established benefits of vaccination for physical health protection and the potential for psychological effects in vulnerable individuals.